Compared with anastrozole alone, the combination of fulvestrant and anastrozole significantly improved time without disease progression and extended the median overall survival of women with endocrine-responsive metastatic breast cancer; offering a new standard-of-care for these women. Unfortunately, information about the efficacy of the combination in the adjuvant setting is not available.
Key Points
Although this trial may be the basis for a change in clinical practice for patients with advanced-stage hormone receptor-positive breast cancer, no trials on the combination have been conducted to inform about treatment for patients in the adjuvant setting.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Goldhirsch, A. et al. Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann. Oncol. 22, 1736–1747 (2011).
Mehta, R. S. et al. Combination anastrozole and fulvestrant in metastatic breast cancer. N. Engl. J. Med. 367, 435–444 (2012).
Macedo, L. F., Sabnis, G. J., Goloubeva, O. G. & Brodie, A. Combination of anastrozole with fulvestrant in the intratumoral aromatase xenograft model. Cancer Res. 68, 3516–3522 (2008).
Bergh, J. et al. FACT: an open-label randomized phase III study of fulvestrant and anastrozole in combination compared with anastrozole alone as first-line therapy for patients with receptor-positive postmenopausal breast cancer. J. Clin. Oncol. 30, 1897–1900 (2012).
Di Leo, A. et al. Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. J. Clin. Oncol. 28, 4594–4600 (2010).
Baselga, J. et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N. Engl. J. Med. 366, 520–529 (2012).
Bachelot, T. et al. Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: A GINECO Study. J. Clin. Oncol. 30, 2718–2724 (2012).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Goldhirsch, A., Gelber, R. Anastrozole and fulvestrant—combination to unlock efficacy. Nat Rev Clin Oncol 9, 556–557 (2012). https://doi.org/10.1038/nrclinonc.2012.155
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2012.155
